Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Striatal Neuron Excitability Is Regulated by Huntingtin in the Adult Brain.

eNeuro·2026

Same author

Bruton's Tyrosine Kinase-Going Beyond the B Cell.

Immunology·2026

Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026

Same author

Plasma extracellular vesicle sampling from glioblastoma demonstrates a small RNA signature indicative of disease and identifies lncRNA <i>RPPH1</i> as a biomarker.

Neuro-oncology advances·2026

Same author

Cerebrospinal fluid-driven ependymal motile cilia defects are implicated in multiple sclerosis.

Brain : a journal of neurology·2025

Same author

MiR-146b-5p Decreases Cytokine Release From Astrocytes and Preserves Oligodendrocyte Progenitor Cell Complexity During Inflammation.

The European journal of neuroscience·2025

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Targeting apoptosis to treat multiple sclerosis.

Andrea L O Hebb¹, Craig S Moore, Virender Bhan

¹Department of Pharmacology, Dalhousie University, 5850 College Street, Halifax, NS B3H 1X5, Canada.

Current Drug Discovery Technologies

|June 10, 2008

Summary

Inhibitor of apoptosis (IAP) genes are elevated in multiple sclerosis (MS) patients, suggesting they could be diagnostic markers. Targeting these genes, like X-linked IAP (XIAP), may offer new treatments for MS.

More Related Videos

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Published on: February 5, 2015

Targeted Knockdown of Genes in the Choroid Plexus

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Related Experiment Videos

Last Updated: Jul 4, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Published on: February 5, 2015

Targeted Knockdown of Genes in the Choroid Plexus

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Area of Science:

Neuroimmunology
Molecular Biology
Genetics

Background:

Multiple sclerosis (MS) pathogenesis involves impaired apoptosis of myelin-reactive immune cells.
Inhibitor of apoptosis (IAP) proteins are key regulators of programmed cell death.
Elevated IAP expression is implicated in various autoimmune diseases.

Purpose of the Study:

To investigate the role of IAP family genes in multiple sclerosis (MS).
To assess IAPs as potential diagnostic markers for MS subtypes.
To explore the therapeutic potential of targeting IAPs in MS models.

Main Methods:

Quantitative analysis of IAP gene expression in immune cells from MS patients.
Assessment of IAP levels in different MS disease courses (aggressive, relapsing-remitting).
In vivo studies using antisense-mediated knockdown of X-linked IAP (XIAP) in an animal model of MS.

Main Results:

IAP gene family members were found to be elevated in monocytes and T cells of patients with aggressive or relapsing-remitting MS during disease relapse.
These findings suggest IAPs may serve as novel diagnostic markers for distinguishing MS subtypes.
Antisense-mediated knockdown of XIAP demonstrated a reversal of paralysis in an animal model of MS.

Conclusions:

Elevated IAP expression in immune cells correlates with MS activity and severity.
IAPs represent promising diagnostic biomarkers for stratifying MS patients.
Targeting XIAP and potentially other IAPs offers a potential therapeutic strategy for MS treatment.